Antihistamine Structural Variations Aptly With Their Pharmacodynamics And Physicochemical Properties

• Eman M. Hassan

  College of Pharmacy, University of Mosul, Mosul

• Mohamed D. Mahmood

  College of Pharmacy, University of Mosul, Mosul

• Marwan M. Makhan

  College of Pharmacy, University of Mosul, Mosul

General Background: Antihistamines targeting the histamine H1 receptor are crucial therapeutic agents for managing allergic and inflammatory conditions globally. Specific Background: Structural modifications among first-, second-, and third-generation antihistamines directly dictate their lipophilicity, receptor selectivity, and central nervous system penetration. Knowledge Gap: Comprehensive insights linking subtle chemical variations to detailed pharmacodynamics, receptor occupancy, and unexpected therapeutic applications remain fragmented. Aims: This review evaluates how structural diversity influences H1 receptor binding, physicochemical behavior, sedative potential, and clinical outcomes. Results: Non-sedating zwitterionic structures exhibit lower blood-brain barrier permeability and reduced H1 receptor occupancy compared to lipophilic, flexible first-generation compounds. Novelty: Recent structural insights reveal secondary binding pockets and extracellular loop interactions that facilitate novel antiparasitic and migraine therapeutic avenues. Implications: Understanding these structure-activity relationships guides the rational pharmacoengineering of personalized next-generation antihistamines with enhanced safety profiles.

Keywords: Antihistamine Structure, Pharmacodynamics, Physicochemical Properties, Receptor Occupancy, Inverse Agonist

Key Findings Highlights

Structural variations in functional groups dictate blood-brain barrier permeability and central nervous system sedation profiles.

Low brain H1 receptor occupancy in zwitterionic agents ensures peripheral selectivity without impairing psychomotor function.

Unique binding pocket configurations enable potential novel applications ranging from antiparasitic activity to migraine management.

R. Sharma, S. K. Jaiswal, S. Kumar, and M. Yadav, "Structural insights into the binding modes of antihistamines to histamine H1 receptor: Molecular dynamics simulations and free energy calculations," Journal of Biomolecular Structure and Dynamics, vol. 38, no. 10, pp. 2884–2894, 2020.

F. E. R. Simons, K. J. Simons, and E. M. Frith, "The pharmacology and use of H1-receptor-antagonist drugs: Advances and perspectives," New England Journal of Medicine, vol. 384, no. 5, pp. 275–285, 2021.

R. Leurs, M. K. Church, and M. Taglialatela, "H1-antihistamines: Inverse agonism, anti-inflammatory actions and cardiac effects," Clinical & Experimental Allergy, vol. 32, no. 4, pp. 489–498, 2002.

R. A. Bakker, S. B. Schoonus, M. J. Smit, H. Timmerman, and R. Leurs, "Histamine H(1)-receptor activation of nuclear factor-kappa B: Roles for G beta gamma- and G alpha(q/11)-subunits in constitutive and agonist-mediated signaling," Molecular Pharmacology, vol. 60, no. 5, pp. 1133–1142, 2001.

R. A. Bakker, K. Wieland, H. Timmerman, and R. Leurs, "Constitutive activity of the histamine H(1) receptor reveals inverse agonism of histamine H(1) receptor antagonists," European Journal of Pharmacology, vol. 387, no. 1, pp. R5–R7, 2000.

K. Weller and M. Maurer, "Desloratadine inhibits human skin mast cell activation and histamine release," Journal of Investigative Dermatology, vol. 129, no. 11, pp. 2723–2726, 2009.

M. B. Emanuel, "Histamine and the antiallergic antihistamines: A history of their discoveries," Clinical & Experimental Allergy, vol. 29, no. S3, pp. 1–11, 1999.

S. Linton, L. Hossenbaccus, and A. K. Ellis, "Evidence-based use of antihistamines for treatment of allergic conditions," Annals of Allergy, Asthma & Immunology, vol. 131, no. 5, pp. 572–580, 2023.

H. Kawauchi, K. Yanai, D. Y. Wang, K. Itahashi, K. Okubo, and C. Kamei, "Antihistamines for allergic rhinitis treatment from the viewpoint of nonsedative properties," International Journal of Molecular Sciences, vol. 21, no. 5, p. 213, 2020.

F. E. R. Simons, K. J. Simons, and E. M. Frith, "The pharmacology and use of H1-receptor-antagonist drugs: Advances and perspectives," New England Journal of Medicine, vol. 365, no. 14, pp. 1275–1285, 2011.

P. Paśko, T. Rodacki, R. Domagała-Rodacka, K. Palimonka, M. Marcinkowska, and D. Owczarek, "Second generation H1-antihistamines interaction with food and alcohol—A systematic review," Biomedicine & Pharmacotherapy, vol. 93, pp. 27–39, 2017.

G. Ciprandi, M. A. Tosca, C. Cosentino, A. M. Riccio, G. Passalacqua, and G. W. Canonica, "Effects of fexofenadine and other antihistamines on components of the allergic response: Adhesion molecules," Journal of Allergy and Clinical Immunology, vol. 112, no. 4, pp. S78–S82, 2003.

Papi, N. G. Papadopoulos, L. A. Stanciu, K. Degitz, S. T. Holgate, and S. L. Johnston, "Effect of desloratadine and loratadine on rhinovirus-induced intercellular adhesion molecule 1 upregulation and promoter activation in respiratory epithelial cells," Journal of Allergy and Clinical Immunology, vol. 108, no. 2, pp. 221–228, 2001.

N. Schellack, G. Schellack, and M. Janse van Rensburg, "An overview of anti-allergic drug therapy and the histamine-1 antihistamines," South African Family Practice, vol. 57, no. 1, pp. 43–49, 2015.

K. Hiraoka, M. Tashiro, T. Grobosch, M. Maurer, K. Oda, J. Toyohara, K. Ishii, K. Ishiwata, and K. Yanai, "Brain histamine H1 receptor occupancy measured by PET after oral administration of levocetirizine, a non-sedating antihistamine," Expert Opinion on Drug Safety, vol. 14, no. 2, pp. 199–206, 2015.

D. A. McNaught-Flores, A. J. Kooistra, Y. C. Chen, J. A. Arias-Montano, P. Panula, and R. Leurs, "Pharmacological characterization of the zebrafish (Danio rerio) histamine H1 receptor reveals the involvement of the second extracellular loop in the binding of histamine," Molecular Pharmacology, vol. 104, no. 5, pp. 242–253, 2023.

F. E. R. Simons and K. J. Simons, "H1 antihistamines: Current status and future directions," World Allergy Organization Journal, vol. 1, no. 9, pp. 145–155, 2008.

K. Yanai, T. Watanabe, H. Yokoyama, J. Hatazawa, R. Iwata, K. Ishiwata, K. Meguro, M. Itoh, T. Takahashi, and T. Ido, "Mapping of histamine H1 receptors in the human brain using [11C]pyrilamine and positron emission tomography," Journal of Neurochemistry, vol. 59, no. 1, pp. 128–136, 1992.

K. McDonald, L. Trick, and J. Boyle, "Sedation and antihistamines: An update. Review of inter-drug differences using proportional impairment ratios," Human Psychopharmacology: Clinical and Experimental, vol. 23, no. 7, pp. 555–570, 2008.

K. Yanai, D. Zhang, M. Tashiro, T. Yoshikawa, F. Naganuma, R. Harada, T. Nakamura, K. Shibuya, and N. Okamura, "Positron emission tomography evaluation of sedative properties of antihistamines," Expert Opinion on Drug Safety, vol. 10, no. 4, pp. 613–622, 2011.

K. Yanai and M. Tashiro, "The physiological and pathophysiological roles of neuronal histamine: An insight from human positron emission tomography studies," Pharmacology & Therapeutics, vol. 113, no. 1, pp. 1–15, 2007.

S. T. Holgate, G. W. Canonica, F. E. R. Simons, M. Taglialatela, M. Tharp, H. Timmerman, and K. Yanai, "Consensus Group on New-Generation Antihistamines (CONGA): Present status and recommendations," Clinical & Experimental Allergy, vol. 33, no. 9, pp. 1305–1324, 2003.

K. Yanai, T. Yoshikawa, A. Yanai, T. Nakamura, T. Iida, R. Leurs, and M. Tashiro, "The clinical pharmacology of non-sedating antihistamines," Pharmacology & Therapeutics, vol. 178, pp. 148–156, 2017.

K. Hiraoka, K. Yanai, and D.-Y. Watanabe, "Antihistamines for allergic rhinitis treatment from the viewpoint of nonsedative properties," International Journal of Molecular Sciences, vol. 20, no. 2, p. 213, 2019.

D. B. Roquini, B. L. Lemes, A. L. B. Kreutz, S. C. Spoladore, M. C. Amaro, F. B. Lopes, J. P. S. Fernandes, and J. de Moraes, "Antihistamines H1 as potential anthelmintic agents against the zoonotic parasite Angiostrongylus cantonensis," ACS Omega, vol. 9, no. 28, pp. 31159–31165, 2024.

C. Chen, "Physicochemical, pharmacological and pharmacokinetic properties of the zwitterionic antihistamines cetirizine and levocetirizine," Current Medicinal Chemistry, vol. 15, no. 21, pp. 2173–2191, 2008.

K. Farzam, S. Sabir, and M. C. O'Rourke, "Antihistamines," in StatPearls, Treasure Island, FL, USA: StatPearls Publishing, 2024.

L. Li, R. Liu, C. Peng, X. Chen, and J. Li, "Pharmacogenomics for the efficacy and side effects of antihistamines," Experimental Dermatology, vol. 31, no. 7, pp. 993–1004, 2022.

M. K. Church, "Comparative inhibition by bilastine and cetirizine of histamine-induced wheal and flare responses in humans," Inflammation Research, vol. 60, no. 12, pp. 1107–1112, 2011.

Hindmarch and Z. Shamsi, "Antihistamines: Models to assess sedative properties, assessment of sedation, safety and other side-effects," Clinical & Experimental Allergy, vol. 29, no. S3, pp. 133–142, 1999.

P. Kuna, D. Jurkiewicz, M. Czarnecka-Operacz, R. Pawliczak, J. Woroń, M. Moniuszko, and A. Emeryk, "The role and choice criteria of antihistamines in allergy management – Expert opinion," Postępy Dermatologii i Alergologii, vol. 33, no. 6, pp. 397–410, 2016.

Worm, K. Falkenberg, and J. Olesen, "Histamine and migraine revisited: Mechanisms and possible drug targets," The Journal of Headache and Pain, vol. 20, no. 1, p. 30, 2019.

D. Wang, Q. Guo, Z. Wu, M. Li, B. He, Y. Du, K. Zhang, and Y. Tao, "Molecular mechanism of antihistamines recognition and regulation of the histamine H1 receptor," Nature Communications, vol. 15, no. 1, p. 84, 2024.

D. A. McNaught-Flores, A. J. Kooistra, Y. C. Chen, J. A. Arias-Montano, P. Panula, and R. Leurs, "Pharmacological characterization of the zebrafish (Danio rerio) histamine H1 receptor reveals the involvement of the second extracellular loop in the binding of histamine," Molecular Pharmacology, vol. 105, no. 2, pp. 84–96, 2024.